BMY Biopharma · Large cap · Pharma · Dividend · Thesis updated July 19, 2026

New drugs race old patent cliffs

The Growth Portfolio produced $6.2 billion in Q1 2026 revenue and now drives more than half of sales.
Cobenfy started fast with $163 million in Q1 2026 revenue after its schizophrenia launch.
Legacy drugs are shrinking fast, with Revlimid sales down 63% as generic competition expands.
Eliquis grew 13% in Q1, but that quarter benefited from inventory build before a Q2 2026 price cut.
Finn's overall view is balanced: new launches help, but pricing pressure and patent cliffs still weigh on the stock.

01 Running thesis

A hard handoff to newer drugs

Bristol-Myers Squibb is in a transition. Older blockbusters are losing protection, while newer drugs are trying to fill the hole. In Q1 2026, the Growth Portfolio reached $6.2 billion, while the Legacy Portfolio fell to $5.3 billion.

The bull case is that the handoff is working. Cobenfy posted $163 million in Q1 revenue, Camzyos nearly doubled to $314 million, Reblozyl reached $451 million, and Breyanzi grew 53% year over year. Those drugs help offset the expected fall in Revlimid, which dropped 63%.

The bear case is that the math may get harder. Eliquis revenue was $4.1 billion and grew 13% in Q1, but management said that was helped by wholesaler buying before a scheduled Q2 2026 price reduction. Opdivo also looked weaker, down 8%, but management said a U.S. wholesaler inventory drawdown made the quarter look worse.

The next test is simple to state but hard to pass: can new products and cost cuts grow fast enough to beat lower prices, lower margins, and late-decade patent cliffs?

Apr 2026→Q1 2026 showed the core tradeoff more clearly. The Growth Portfolio kept growing, but Eliquis benefited from inventory build before a Q2 price cut and Opdivo was hurt by inventory drawdown.

Apr 2026▲Cobenfy launched with $163 million in Q1 revenue, giving BMY a stronger early proof point in neuroscience. Management also raised its cost savings target to $2 billion by the end of 2027.

Feb 2026▼The 2025 10-K added pressure to the pricing story. BMY disclosed a U.S. government agreement that included providing Eliquis to Medicaid for free starting January 1, 2026.

Oct 2025▲Q3 2025 showed the Growth Portfolio's dollar growth outpacing Legacy Portfolio erosion. Camzyos, Breyanzi, and Eliquis were key contributors, though Eliquis price quality stayed uncertain.

Jul 2025▲Q2 2025 was a positive inflection point because Growth Portfolio gains exceeded Legacy Portfolio declines. Breyanzi, Camzyos, and Reblozyl drove the improvement.

Apr 2025▼Q1 2025 confirmed that Medicare Part D redesign was already hurting U.S. Eliquis pricing. Revlimid also fell sharply, raising the urgency of the portfolio transition.

Feb 2025→The 2024 10-K framed the main story as execution, not strategy. Cobenfy and Krazati moved into the bull case, while IRA price setting for Eliquis and Pomalyst sharpened the bear case.

Oct 2024▲FDA approval of Cobenfy reduced regulatory risk for the Karuna deal. The focus shifted to whether BMY could turn the approval into a large commercial product.

02 Business model

Patents turn science into sales

Bristol-Myers Squibb makes money by selling prescription drugs that are protected by patents. These drugs treat serious diseases in oncology, hematology, immunology, cardiovascular disease, and neuroscience.

The model can be very profitable while patents last. It can also break quickly when a top drug loses exclusivity, which means cheaper generic or biosimilar versions can enter the market. That is already happening with Revlimid and Pomalyst/Imnovid.

Management is trying to make the company leaner at the same time. Its Strategic Productivity Initiative targets $2 billion in cost savings by the end of 2027, using shorter research cycle times, AI in R&D, and commercial efficiencies.

BMY also buys growth when it needs to. Recent deals added Karuna in neuroscience, RayzeBio in radiopharmaceuticals, and Mirati in targeted oncology. Those deals raise the stakes for launch execution and pipeline data.

03 Product portfolio

Where the drug mix is shifting

Cash cow

Eliquis

Eliquis is a major blood thinner and reported $4.1 billion in Q1 2026 revenue. The risk is price pressure, since Q1 growth benefited from inventory build before a scheduled Q2 2026 price reduction.

Cash cow

Opdivo and Opdivo Qvantig

Opdivo is a large cancer immunotherapy franchise with $2.1 billion in Q1 2026 revenue. Sales fell 8%, partly due to a U.S. wholesaler inventory drawdown, and BMY is shifting patients toward the under-the-skin version called Opdivo Qvantig.

Growth engine

Cobenfy

Cobenfy is BMY's key new neuroscience launch for schizophrenia. It delivered $163 million in Q1 2026 revenue, and the company is testing it in Alzheimer's psychosis.

Growth engine

Camzyos

Camzyos treats obstructive hypertrophic cardiomyopathy, a heart condition that can block blood flow. Q1 2026 revenue nearly doubled to $314 million as it reached more patients globally.

Growth engine

Reblozyl

Reblozyl treats anemia tied to certain blood disorders. It produced $451 million in Q1 2026 revenue, up 15% year over year.

Option

Breyanzi

Breyanzi is a cell therapy for certain blood cancers. It grew 53% year over year in Q1 2026, making it an important but still specialized growth product.

Cash cow

Revlimid and Pomalyst/Imnovid

These legacy blood cancer drugs are now under heavy generic pressure. Revlimid fell 63% to $349 million in Q1 2026, and Pomalyst/Imnovid also faces generic entry.

04 Business segments

Mostly a U.S. drug company

United States70%declining

International30%modest

The mix uses Q1 2026 revenue by geography: $7.8 billion from the United States and $3.4 billion from international markets. U.S. results are more exposed to Medicare and IRA price pressure.

05 Risk factors

What could break the bridge

Eliquis price reset

High impact · High odds

Eliquis is still one of BMY's biggest products, but the Q1 2026 result was helped by wholesaler buying before a scheduled Q2 2026 price reduction. That makes the true demand trend harder to read. IRA price setting also puts direct pressure on this product starting in 2026.

We watchQ2 and Q3 2026 Eliquis revenue, average net selling price, and gross margin.

Legacy cliff gets steeper

High impact · High odds

Revlimid fell 63% in Q1 2026 as generic lenalidomide competition widened in the U.S. Pomalyst/Imnovid is also under pressure from generic entry. If these declines move faster than the Growth Portfolio can rise, total revenue can stall or fall.

We watchQuarterly sales for Revlimid and Pomalyst/Imnovid versus total Growth Portfolio revenue.

Opdivo defense may not hold

Medium impact · Medium odds

Opdivo remains a major cancer franchise, but Q1 2026 sales were down 8%. Management said wholesaler inventory hurt the quarter, while it also pushes conversion to Opdivo Qvantig, the subcutaneous version. The open question is whether Qvantig can protect share before late-decade loss of exclusivity pressure.

We watchOpdivo Qvantig uptake, total Opdivo franchise sales, and patient conversion from IV Opdivo.

Pipeline readout risk

High impact · Medium odds

BMY needs future products to replace revenue that could be lost from Eliquis and Opdivo later in the decade. Milvexian data in atrial fibrillation and secondary stroke prevention, plus Cobenfy data in Alzheimer's psychosis, are high-stakes events. Bad data would shrink the future growth bridge.

We watchMilvexian AFib and secondary stroke prevention results, plus Cobenfy ADEPT trial updates.

More government price setting

Medium impact · High odds

The portfolio's exposure to U.S. government price setting is growing. Eliquis is affected in 2026, Pomalyst in 2027, and Orencia was selected for negotiation beginning in 2028. More selected drugs could weigh on revenue and margins.

We watchHHS negotiation lists, final maximum fair prices, and management comments on net price.

06 Quick answers

In one breath

Why is Bristol-Myers Squibb under pressure?

Several older drugs are losing exclusivity, which lets cheaper rivals take share. At the same time, U.S. pricing pressure is rising for drugs like Eliquis, Pomalyst, and Orencia.

What is the main bull case for BMY?

The bull case is that newer drugs can outgrow the legacy decline. Cobenfy, Camzyos, Reblozyl, Breyanzi, and other Growth Portfolio products are the center of that case.

Why does Eliquis matter so much?

Eliquis is a large blood thinner franchise with $4.1 billion in Q1 2026 revenue. Its scheduled Q2 2026 price reduction is one of the clearest near-term tests for BMY's revenue and margins.

What is Opdivo Qvantig?

Opdivo Qvantig is a subcutaneous version of Opdivo, meaning it is given under the skin instead of by IV infusion. BMY hopes it can make the franchise harder to displace as future competition rises.